Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pan-tumor long-term extension study of nivolumab and other cancer therapies in patients previously enrolled in BMS trials
CTR20210444Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in cancer, sponsored by Bristol Myers Squibb. Started Aug 2022; status: active.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on CTR20210444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210444.